BIOT 📈 Biotage AB - Overview
Exchange: ST • Country: Sweden • Currency: SEK • Type: Common Stock • ISIN: SE0000454746
BIOT: Lab Equipment, Reagents, Consumables, Sample Preparation, Purification Systems
Biotage AB is a company that specializes in providing a wide range of solutions and products for various industries, including drug discovery and development, analytical testing, and water and environmental testing. Their product portfolio includes organic and peptide synthesis solutions, such as flash chromatography, evaporation, and work-up products, as well as sample preparation products and plasmid purification solutions. Additionally, they offer oligo synthesis solutions, metal scavengers, and reagents, along with accessories and spare parts. This comprehensive range of products enables Biotage AB to cater to the diverse needs of its customers.
The company's sample preparation solutions are designed to serve multiple areas, including clinical and bioanalytical, forensic and toxicology, doping control, environment, and food and agriculture. These solutions are complemented by a range of consumables and systems, which facilitate efficient and accurate sample preparation. Furthermore, Biotage AB provides protein purification solutions, including antibody and tagged proteins purification, automation systems, and custom packing services. Their PhyTip columns, which are available in various formats such as ion exchange, reversed phase, normal phase, and gel filtration, are designed to support a wide range of purification needs.
Biotage AB's customer base is diverse and global, comprising pharmaceutical and biotechnical companies, contract research and manufacturing organizations, diagnostics, clinical, environmental protection, food safety, forensic, and academic laboratories. With operations in over 80 countries across the Americas, Europe, the Middle East, Africa, and Asia Pacific, the company has established a significant presence in the global market. Founded in 1969 and headquartered in Uppsala, Sweden, Biotage AB has a long history of delivering innovative solutions and products to its customers, and its website can be accessed at https://www.biotage.com. The company's stock is listed as a common stock, with the ISIN SE0000454746, and is classified under the GICS Sub Industry: Life Sciences Tools & Services.
Additional Sources for BIOT Stock
BIOT Stock Overview
Market Cap in USD | 1,175m |
Sector | Healthcare |
Industry | Medical Instruments & Supplies |
GiC Sub-Industry | Life Sciences Tools & Services |
IPO / Inception |
BIOT Stock Ratings
Growth 5y | 18.9% |
Fundamental | 43.9% |
Dividend | 44.9% |
Rel. Strength Industry | 973 |
Analysts | - |
Fair Price Momentum | 147.71 SEK |
Fair Price DCF | 78.21 SEK |
BIOT Dividends
Dividend Yield 12m | 1.01% |
Yield on Cost 5y | 1.34% |
Annual Growth 5y | 1.30% |
Payout Consistency | 87.2% |
BIOT Growth Ratios
Growth Correlation 3m | -71.2% |
Growth Correlation 12m | 27.4% |
Growth Correlation 5y | 12.7% |
CAGR 5y | 5.96% |
CAGR/Mean DD 5y | 0.21 |
Sharpe Ratio 12m | 0.63 |
Alpha | -2.09 |
Beta | 0.97 |
Volatility | 38.16% |
Current Volume | 80.7k |
Average Volume 20d | 153.1k |
As of December 21, 2024, the stock is trading at SEK 159.70 with a total of 80,721 shares traded.
Over the past week, the price has changed by -2.51%, over one month by +7.21%, over three months by -12.73% and over the past year by +25.03%.
Partly, yes. Based on ValueRay Fundamental Analyses, Biotage AB (ST:BIOT) is currently (December 2024) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 43.86 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BIOT as of December 2024 is 147.71. This means that BIOT is currently overvalued and has a potential downside of -7.51%.
Biotage AB has no consensus analysts rating.
According to ValueRays Forecast Model, BIOT Biotage AB will be worth about 164 in December 2025. The stock is currently trading at 159.70. This means that the stock has a potential upside of +2.67%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 202.7 | 26.9% |
Analysts Target Price | - | - |
ValueRay Target Price | 164 | 2.7% |